DDW: Industry trends and predictions for 2025
Megan Thomas of Drug Discovery World (DDW) spoke with Martha Stone, CEO of Steritas, and other industry experts about their predictions for drug discovery opportunities in 2025. Read the article here.
Steritas announces collaboration with argenx to advance evidence for novel steroid-sparing therapeutics
First-in-class steroid-toxicity outcome assessments licensed by argenx to support the development of novel steroid-sparing therapeutics for autoimmune diseases Boston, MA, USA, 19 November 2024: ...
Alder-Hey Children’s NHS Foundation Trust and Liverpool Clinical Trials Centre led clinical trial to compare effectiveness and to assess steroid-toxicity in children with juvenile idiopathic arthritis
Study will allow researchers to assess the outcomes of intravenous and oral glucocorticoid protocols in children Boston, MA, USA, 24 September 2024: Steritas LLC., a company dedicated to enhancing ...
Steritas Named 2023 Startup of the Year
Steritas is very pleased to have been named Startup of the Year during the 2023 SAMPS Awards. The annual SAMPS awards celebrate companies that are doing important work in the life science and applied ...
ACR Convergence 2023. November 10-15, San Diego
John H. Stone, MD MPH & Martha N. Stone will attend ACR Convergence 2023, the world's premier rheumatology meeting.
Healio Rheuminations Podcast: The Glucocorticoid Toxicity Index with John Stone, MD MPH
Glucocorticoids can do a lot of harm over time. In this podcast episode, John Stone, MD, MPH, walks us through the Glucocorticoid Toxicity Index, a validated tool to measure steroid toxicity over ...